Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

GLIOLAN, POWDER FOR ORAL SOLUTION, 30 MG/ML [SIN15244P]

Active ingredients: AMINOLEVULINIC ACID 23.4 MG/ML EQUIVALENT AMINOLEVULINIC ACID HYDROCHLORIDE

View product's general information
Last updated on 9 October 2026

Product Info

GLIOLAN, POWDER FOR ORAL SOLUTION, 30 MG/ML

[SIN15244P]

Product information

Active Ingredient and Strength

AMINOLEVULINIC ACID 23.4 MG/ML EQUIVALENT AMINOLEVULINIC ACID HYDROCHLORIDE - 30 MG/ML

Dosage Form

POWDER, FOR SOLUTION

Manufacturer and Country

LYOCONTRACT GMBH - GERMANY

Registration Number

SIN15244P

Licence Holder

LINK HEALTHCARE SINGAPORE PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

L01XD04

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications

Gliolan is indicated in adults for visualisation of malignant tissue during surgery for malignant glioma (WHO grade III and IV).

Dosing

4.2 Posology and method of administration

This medicinal product should only be used by experienced neurosurgeons conversant with surgery of malignant gliomas and in-depth knowledge of functional brain anatomy who have completed a training course in fluorescence-guided surgery.

Posology
The recommended dose is 20 mg 5-ALA HCl per kilogram body weight.

The total number of bottles needed to achieve the intended dose for the individual patient can be determined according to the equation below (rounded up to the nearest whole bottle):

Gliolan Dosage Formula 1



The administration volume needed to achieve the intended dose for the individual patient can be calculated according to the equation below:

Gliolan Dosage Formula 2



Renal or hepatic impairment
No trials have been performed in patients with clinically relevant hepatic or renal impairment. Therefore, this medicinal product should be used with caution in such patients.

Elderly
There are no special instructions for use in elderly patients with regular organ function.

Paediatric population
The safety and efficacy of Gliolan in children and adolescents aged 0 to 18 years have not yet been established. No data are available.

Method of administration
The solution should be administered orally three hours (range 2–4 hours) before anaesthesia. Use of 5-ALA under conditions other than the ones used in the clinical trials entail an undetermined risk.

If the surgery is postponed by more than 12 hours, surgery should be re-scheduled for the next day or later. Another dose of this medicine can be taken 2 – 4 hours before anaesthesia.

Precautions to be taken before handling or administering the medicinal product
For instructions on reconstitution of the medicinal product before administration, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Contraindications

4.3 Contraindications

  • Hypersensitivity to the active substance or porphyrins.

  • Acute or chronic types of porphyria.

  • Pregnancy (see sections 4.6 and 5.3 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).